CN1562073A - Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate - Google Patents
Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate Download PDFInfo
- Publication number
- CN1562073A CN1562073A CN 200410038821 CN200410038821A CN1562073A CN 1562073 A CN1562073 A CN 1562073A CN 200410038821 CN200410038821 CN 200410038821 CN 200410038821 A CN200410038821 A CN 200410038821A CN 1562073 A CN1562073 A CN 1562073A
- Authority
- CN
- China
- Prior art keywords
- chondroitin sulfate
- injection
- molecular weight
- preparation
- type preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229920001287 Chondroitin sulfate Polymers 0.000 title claims abstract description 85
- 229940059329 chondroitin sulfate Drugs 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 75
- 238000002347 injection Methods 0.000 title abstract description 8
- 239000007924 injection Substances 0.000 title abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims abstract description 8
- RSYSVNVHLXTDIR-ZZMNMWMASA-L (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate;manganese(2+) Chemical compound [Mn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RSYSVNVHLXTDIR-ZZMNMWMASA-L 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000006071 cream Substances 0.000 claims abstract description 6
- 239000003889 eye drop Substances 0.000 claims abstract description 5
- 239000000499 gel Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 10
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 9
- 229960002442 glucosamine Drugs 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 4
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002505 iron Chemical class 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- -1 amino glucose Chemical compound 0.000 abstract description 7
- 239000007901 soft capsule Substances 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 15
- 239000008107 starch Substances 0.000 description 15
- 235000019698 starch Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 206010049040 Weight fluctuation Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 235000012716 cod liver oil Nutrition 0.000 description 2
- 239000003026 cod liver oil Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229950004959 sorbitan oleate Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- DYIOQMKBBPSAFY-BENRWUELSA-N Palmityl myristoleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCC DYIOQMKBBPSAFY-BENRWUELSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000607122 Uncaria tomentosa Species 0.000 description 1
- ACOGMWBDRJJKNB-UHFFFAOYSA-N acetic acid;ethene Chemical group C=C.CC(O)=O ACOGMWBDRJJKNB-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000011472 cat’s claw Nutrition 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229940093532 cetyl myristoleate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical group CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229940021741 glucosamine hydrochloride 500 mg Drugs 0.000 description 1
- 229940030836 glucosamine sulfate 250 mg Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940116298 l- malic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- DYIOQMKBBPSAFY-UHFFFAOYSA-N palmityl myristoleate Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCC=CCCCC DYIOQMKBBPSAFY-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229920005643 polyisobutyl cyanoacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a non-injection preparation containing medium and/or low molecular weight chondroitin sulfate having average molecular weight in a scope of 2,000-30,000 daltons, which contains a pharmaceutically acceptable auxiliary material, and may also contains pharmaceutic salts including amino glucose, manganese ascorbate as well as other auxiliary elements. The inventive non-injection preparation may be the agent types such as tablet, capsule, soft capsules, granula, membrane agent, sprays, pills, eye drops, solution agents, gels, and creams, etc., and the preparation may also be used as medicine, health-care food or cosmetics. Compared with ordinary non-injection preparation of the chondroitin sulfate, this kind of medium and/or low molecular weight chondroitin sulfate non-injection preparation is more easy to absorb by the human body, and can satisfy the strict requirement of clinical medication for the product quality of the chondroitin sulfate.
Description
Technical field
The present invention relates to a kind of non-injection-type preparation of chondroitin sulfate, particularly relate to a kind of mean molecule quantity that contains 2 with therapeutical effect or health-care effect, 000-30, in 000 dalton's scope, in and/or the non-injection-type preparation of the aching and limp ossein of low-sulfur.
Technical background
Chondroitin sulfate be a kind of with animals such as pig, cattle, sheep cartilaginous tissue and the cartilage of aquatic products such as shark be raw material, the macromolecular acid mucopolysaccharides that utilizes biochemical extraction process technology to make.The sodium salt of chondroitin sulfate, potassium salt, calcium salt, zinc salt etc. are widely used in medicine, health promoting product, food, cosmetics, feed for pet etc.Chondroitin sulfate has different physiological roles, play an important role keeping on tissue and the immune function, can be used for the treatment of multiple disease, diseases such as treatment osteoarthritis, arthralgia, hyperlipidemia, hypercholesterolemia, coronary heart disease, arteriosclerosis, angina pectoris, myocardial ischemia, myocardial infarction, tumor, nerve injury, nervous headache, neuralgia, keratitis, corneal ulcer, corneal injury; Can also and drug combinations such as glucosamine, Manganese ascorbate, play the arthritic effect of good control.
The chondroitin sulfate product is normally about 40 with a kind of mean molecule quantity, 000-50, and 000 daltonian water-soluble polymer form exists, and wherein, sulphuric acid is connected on the disaccharide that repeats to combine with ehter bond.The chondroitin sulfate product is generally the mixture of chondroitin sulfate A and these two kinds of main configurations of chondroitin sulfate C.There are big, the shortcomings such as oral absorption is poor, bioavailability is low, curative effect instability of molecular weight fluctuation in common chondroitin sulfate preparation.This is that its pharmacologically active and molecular weight have confidential relation because the biological activity of chondroitin sulfate is different and different with molecular weight.U.S. Pat 3,405, point out in 120: when the mean molecule quantity of chondroitin sulfate 2,000-6, during 000 dalton, its pharmacologically active is the strongest, has better therapeutic to preventing and treating aspects such as atherosclerosis, rheumatic inflammation and wound healing.Low-molecular-weight chondroitin sulfate has better clinical effect than the chondroitin sulfate of common molecular weight.
The chondroitin sulfate of common molecular weight has been used to prepare the pharmaceutical preparation of treatment and some disease.For example, in American-European countries, the chondroitin sulfate of common molecular weight is widely used as supplementary (Dietary Supplement) owing to take safety, is mainly used in the senile osteoarthrosis of improvement and degenerates, eases the pain.This series products is normal forms compound preparation with compatibilities such as sulphuric acid/glucosamine hydrochloride, MSM, with the increase curative effect.In Japan, the non-injection-type preparation that also has the people that chondroitin sulfate is made is used for the treatment of arthritis.For example: in the open JP2002-154968 of Japan special permission, disclose a kind of chrondroitin or its salt and glucosamine or its salt and seal oil (ァ ザ ラ シ oil) of containing, be used for arthritic prevention, treatment or improve the compositions of symptom.Again for example: Japanese patent application publication No. is that the patent application of JP2003-155250 discloses a kind of Orally administered composition, contains extract, glucosamine, chondroitin sulfate and the collagen of Radix Ranunculi Ternati (キ ャ ッ Star Network ロ one) in the said composition.But, all be the indefinite chondroitin sulfate of molecular weight because prior art adopts, so the effective dose instability, thereby the clinical efficacy shakiness caused.
At the above-mentioned deficiency of prior art, it is the patent application of CN03114375.X and 03152772.8 that the present application people has submitted application number to, discloses in the preparation/method of low-molecular weight chondroitin sulfate.These methods are poor at the indeterminate oral absorption that causes of the molecular weight of chrondroitin, shortcomings such as bioavailability is low, curative effect instability, a kind of method that comprises steps such as acidolysis, ultrafilter membrane separate, the sodium filter membrane concentrates has been proposed, thereby can make average molecular weight range is 2,000-30,000 daltonian chondroitin sulfate.In addition, the present inventor is in the patent application of CN03114374.1 at application number also, discloses a kind of low-molecular weight chondroitin sulfate injection and preparation method thereof.
But the more some other non-injection-type dosage form produce effects of the injection type of chondroitin sulfate is fast, but the patient is very inconvenient in use, is not suitable for long-term prescription, and the injection-type dosage form can not adapt to the purposes that promotes topical therapeutic aspects such as wound healing.Therefore, be necessary to research and develop the non-injection-type preparation that molecular weight concentrates on the chondroitin sulfate in the higher molecular weight ranges of pharmacologically active, to adapt to the needs of clinical application.
Summary of the invention
The purpose of this invention is to provide a kind of mean molecule quantity 2,000-30, the non-injection-type preparation of the chondroitin sulfate in 000 dalton's scope.
Molecular weight chondroitin sulfate and/or low-molecular weight chondroitin sulfate and/or both pharmaceutical salts in containing in the non-injection-type preparation of the present invention, middle molecular weight chondroitin sulfate is that mean molecule quantity is 10,000-30, chondroitin sulfate in 000 dalton's scope, low-molecular weight chondroitin sulfate is a mean molecule quantity 2,000-10, the chondroitin sulfate in 000 dalton's scope; Also contain pharmaceutically acceptable adjuvant in this non-injection-type preparation, and its dosage form is to be selected from a kind of in the following dosage forms: tablet, capsule, granule, solution, gel, cream, aerosol, membrane, pill, suppository and eye drop.
Above-mentioned tablet can be ordinary tablet, coated tablet, Film coated tablets, special-shaped tablets, enteric coatel tablets, slow releasing tablet, controlled release tablet, chewable tablet, effervescent tablet, dispersible tablet etc.Capsule can be common hard capsule, enteric coated capsule, slow releasing capsule, controlled release capsule, soft capsule etc.Solution can be oral administration solution, the agent of external rinse solution.Cream can be the cream of general action or local action.Aerosol also can be induction type or local topical type.Certainly, except the above-mentioned dosage form of enumerating, can also be other non-injection-type preparation.
Non-injection-type preparation of the present invention in direct employing and/or the low-molecular weight chondroitin sulfate, can also adopt the form of its salt, and perhaps both adopt simultaneously.The pharmaceutical salts that can adopt has: sodium salt, potassium salt, calcium salt, zinc salt, iron salt, magnesium salt, aluminum salt etc.Certainly, also can be other officinal salt.
In of the present invention and/or in the non-injection-type preparation of low-molecular weight chondroitin sulfate, both can only contain mean molecule quantity 10,000-30, middle molecular weight chondroitin sulfate between 000 dalton, also can only contain mean molecule quantity, 000-10, the low-molecular weight chondroitin sulfate between 000 dalton 2, certainly, also can contain middle molecular weight chondroitin sulfate and low-molecular weight chondroitin sulfate simultaneously.
The present invention adopts some advanced preparation technique in above-mentioned dosage form.For example: slow release, controlled release, long-acting, Transdermal absorption, mucosa absorption, target administration, directed release, nanometer, micropill, film coating etc., to reach the raising bioavailability, reduce the patient to take number of times, purpose such as be convenient for carrying and preserve.
What preparation was slow, the method for the oral formulations of controlled release is commonly used has: pharmaceutical pack is hidden in the erodible skeleton and with pharmaceutical pack ensconces in the hydrophilic colloidal material.Adjuvant commonly used mainly contains blocker, framework material and thickening agent.Blocker has Animal fat, Cera Flava, Brazil wax, hydrogenated vegetable oil, stearyl alcohol, glycerol monostearate etc.These blocker can be used as erodible framework material, also can be used as the sustained release coating material.Framework material comprises hydrophilic colloid framework material and insoluble framework material.The hydrophilic colloid framework material has methylcellulose, sodium carboxymethyl cellulose, hypromellose, polyvidone, carbopol, alginate, takes off acetyl chitin etc.Insoluble framework material has ethyl cellulose, polymethacrylates, non-toxic polyvinyl chloride, polyethylene, ethylene one acetate ethylene copolymer, silicone rubber etc.Thickening agent is commonly used gelatin, PVP, CMC, PVA, dextran etc.
Non-injection-type preparation of the present invention can be in only containing, low-molecular weight chondroitin sulfate and acceptable adjuvant pharmaceutically, also can be the other drug that has also contained adjuvant treatment effect.For example, can add the glucosamine with similar effect or assosting effect pharmaceutical salts, methylsulfonyl methane (MSM, methyl-sulfonylmethane), Manganese ascorbate, vitamin C, collagen, seal oil, Radix Ranunculi Ternati (Uncaria tomentosa), hyaluronate sodium, vitamin B
12And the various detoxifcation factors, anti-inflammatory factors, analgesic etc., use with the form of compound recipe.
Specifically, the pharmaceutical salts of glucosamine (when being used to prepare the preparation of treatment of arthritis) can be wherein one or more of its sulfate, hydrochlorate, nitrate, iodized salt.Preferably, the pharmaceutical salts of glucosamine adopts sulfate and/or hydrochlorate.Because the sulfate of glucosamine and the effect of hydrochlorate are roughly the same, so more preferably, adopt its sulfate or its hydrochlorate separately.
The detoxifcation factor can be a L MALIC ACID etc.Anti-inflammatory factors can be methylsulfonyl methane, spermaceti olefin(e) acid fat (cetyl myristoleate) etc.Analgesic can be the NSAID (non-steroidal anti-inflammatory drug) with analgesic activity, for example aspirin etc.
Non-injection-type preparation of the present invention can add acceptable adjuvant on any pharmaceutics in preparation process.
For example, in tablet, can add acceptable adjuvant on any pharmaceutics.For example filler, absorbent, wetting agent, binding agent, disintegrating agent, lubricant etc.Can also add coloring agent, sweeting agent, aromatic etc. as required.Filler can adopt starch, microcrystalline Cellulose, pregelatinized Starch, dextrin etc.Absorbent can adopt starch, calcium sulfate, calcium hydrogen phosphate, is used to absorb volatile oil or liquid component, if added seal oil, can add an amount of absorbent as required.Wetting agent can adopt water or ethanol.Binding agent can adopt polyvidone, starch slurry, hypromellose etc.Disintegrating agent can adopt cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose etc.Lubricant can adopt magnesium stearate, Pulvis Talci, stearic acid etc.
In capsule and granule, can add filler, wetting agent, binding agent etc. as required.
Can add antiseptic, correctives in the oral liquid.If make syrup, also should add dense aqueous sucrose solution.
Can add substrate in the pill, for example: stearic acid, monostearate etc.
What deserves to be mentioned is, of the present invention in and/or some exterior-applied formulation of low-molecular weight chondroitin sulfate have the curative effect that promotes wound healing, prevents post-operative wound adhesion aspect.For example, membrane, aerosol, eye drop, solution etc.Membrane can be used to prevent the post-operative wound adhesion.Solution can be used for flushings such as large tracts of land open wound, eye, bladder.
In the non-injection-type preparation of the present invention employed in and/or low-molecular weight chondroitin sulfate can adopt the method for operations such as comprising acid hydrolysis, alkali neutralization, separation, ultrafiltration, nanofiltration to be prepared, the chondroitin sulfate molecular weight can stably be controlled at middle molecular weight (mean molecule quantity 10,000-30,000 dalton) or low-molecular-weight (mean molecule quantity 2,000-10,000 dalton) in the scope.Specifically, in the powder injection formulation of the present invention employed in and/or low-molecular weight chondroitin sulfate can adopt the method preparation of following steps:
(1) chondroitin sulfate with common molecular weight carries out acid hydrolysis;
(2) product behind the above-mentioned acid hydrolysis carries out the alkali neutralization, is adjusted under the alkali condition of pH=8-11, carries out centrifugalize then, removes the precipitation of foreigh protein removing;
(3) transfer pH to neutral the supernatant of above-mentioned steps (2) gained, carry out ultrafiltration then, hold back chondroitin sulfate and the impurity of removing macromolecule;
(4) filtrate of step (3) gained is carried out nanofiltration and concentrate, remove inorganic salt and small molecular weight impurity.
Because chondroitin sulfate of the present invention can reach medicinal standard, therefore, non-injection-type preparation of the present invention both can become medicine according to the quality of production metric system of medicine, also can add auxiliary element and make health food, perhaps make the cosmetics that cream, gel etc. have preserving moisture, promote the skin metabolism effect according to the production standard of food.
Non-injection-type preparation of the present invention can be applied to treat diseases such as osteoarthritis, arthralgia, hyperlipidemia, hypercholesterolemia, coronary heart disease, arteriosclerosis, angina pectoris, myocardial ischemia, myocardial infarction, tumor, nerve injury, nervous headache, neuralgia, keratitis, corneal ulcer, corneal injury, promotes wound healing in addition, prevents effects such as post-operative wound adhesion.
In of the present invention and/or the non-injection-type preparation of low-molecular weight chondroitin sulfate, molecular weight is starkly lower than the national standard of chondroitin sulfate, overcome the big shortcoming of molecular weight fluctuation of common chondroitin sulfate product, had more significant pharmacological action, be more conducive to absorption of human body.
Below, further specify the present invention in conjunction with the embodiments.But the present invention is not limited to these embodiment, and any alternative or improvement that does not depart from center of the present invention spirit still belongs to desired protection domain in claims of the present invention.
The specific embodiment
Embodiment 1
The prescription of tablet (make 1,000, every contains middle molecular weight sodium chondroitin sulfate 400mg):
Mean molecule quantity is 16,000 middle molecular weight sodium chondroitin sulfate 400g
Starch 40g
Starch slurry (10%) 24g
Dried starch 24g
Magnesium stearate 3g
Preparation method:
Get the various materials of above-mentioned formula ratio, middle molecular weight sodium chondroitin sulfate is crossed 80 mesh sieves, with the starch mixing, add starch slurry and make soft material, granulate, put 70-80 ℃ of dry back in 12 mesh sieve granulate with 14 mesh sieves, after adding dried starch and magnesium stearate mixing, tabletting, promptly.
Embodiment 2
The prescription of film coating liquid:
Hydroxypropyl emthylcellulose (HPMC) 2g
Tween 80 1mL
Oleum Ricini 1mL
Phthalic acid diethyl fat 1mL
Pulvis Talci 2g
60% ethanol 100mL
Preparation method:
The middle molecular weight sodium chondroitin sulfate label that the method for embodiment 1 is made carries out coating pan coating or fluidized bed coating coating with above-mentioned film coating liquid, then with river wax polishing promptly.
Embodiment 3
The prescription of compound tablet (make 1,000 altogether, every contains middle molecular weight sodium chondroitin sulfate 200mg, glucosamine sulfate 250mg, MSM 200mg):
Mean molecule quantity 12,000 daltonian middle molecular weight sodium chondroitin sulfate 200g
Glucosamine sulphate 250g
MSM 200g
Pregelatinized Starch is an amount of
Hypromellose is an amount of
Cross-linking sodium carboxymethyl cellulose is an amount of
Magnesium stearate is an amount of
Preparation method: the various materials of getting above-mentioned formula ratio, middle molecular weight sodium chondroitin sulfate, glucosamine sulphate and MSM are crossed 80 mesh sieves, with the pregelatinized Starch mixing, add hypromellose and make soft material, granulate with 14 mesh sieves, put 70-80 ℃ of dry back in 12 mesh sieve granulate, add an amount of cross-linking sodium carboxymethyl cellulose and magnesium stearate mixing after, tabletting, promptly.
Embodiment 4
The prescription of effervescent tablet (make 1,000 altogether, every contains middle molecular weight sodium chondroitin sulfate 400mg):
Mean molecule quantity is 16,000 daltonian middle molecular weight sodium chondroitin sulfate 400g
Vitamin C 30g
Tartaric acid 40g
Sodium bicarbonate 25g
Beta-schardinger dextrin-345g
Lactose 150g
Micropowder silica gel is an amount of
Preparation method: said components is sieved, and mix homogeneously is granulated with the ethanol wetting agent, and dry under 60 ℃ condition, tabletting promptly.
Embodiment 5
The prescription of chewable tablet:
Mean molecule quantity is 16,000 daltonian middle molecular weight sodium chondroitin sulfate 400mg
Xylitol 300mg
Magnesium stearate 10mg
Preparation method: with sodium chondroitin sulfate and xylitol system soft material, granulate, drying, tabletting is promptly.
Embodiment 6
The prescription of hard capsule (make 1,000 of hard capsule altogether, every capsules contains middle molecular weight Zinc chondroitin sulfate. 400mg, glucosamine hydrochloride 500mg):
Mean molecule quantity is 12,000 daltonian chondroitin sulfate zinc salt 400g
Glucosamine hydrochloride 500g
Starch is an amount of
Preparation method: with Zinc chondroitin sulfate. and glucosamine hydrochloride and the abundant mixing of appropriate amount of starch, inspect by ready samples qualified after, insert in the capsulae vacuus, promptly.
Embodiment 7
The prescription of soft capsule (make 1,000 of soft capsule altogether, every soft capsule contains calcium chondroitin sulfate 400mg):
Mean molecule quantity 16,000 daltonian middle molecular weight chondroitin sulfate calcium salt 400g
Cod-liver oil or concise edible vegetable oil are an amount of
Preparation method:
Get calcium chondroitin sulfate, adding cod-liver oil or concise edible vegetable oil are an amount of, make suspension, are that main soft capsule material is made the uniform film of thickness with gelatin, and medicinal liquid is placed two films, are pressed into the ellipse soft capsule with steel mould or rotating mould, promptly.
Embodiment 8
The prescription of oral liquid (make every 10mL solution altogether and contain chondroitin sulfate calcium salt 400mg):
Mean molecule quantity is 10,000 daltonian chondroitin sulfate calcium salts 1,000g
Distilled water adds to 25,000mL
Preparation method:
Get calcium chondroitin sulfate, adding distil water 20 after the 000mL dissolving, adds an amount of distilled water again, makes full dose become 25,000mL, and packing, promptly.
Embodiment 9
The prescription of sterile solution agent:
Mean molecule quantity is 16,000 daltonian low-molecular weight chondroitin sulfate zinc salt 30g
Distilled water adds to 1,000mL
Preparation method:
Get in the hot distilled water that chondroitin sulfate adds about 900mL and dissolve, put coldly, filter, add distilled water and make into 1 on filter, 000mL stirs evenly, and packing is sterilized, promptly.
Embodiment 10
The prescription of granule (make granule 2 altogether, 000g, every gram granule contains chondroitin sulfate plain sheet 200mg, Manganese ascorbate 50mg):
Mean molecule quantity 12,000 daltonian middle molecular weight chondroitin sulfate iron salt 400g
Manganese ascorbate 100g
Starch is an amount of
Starch slurry is an amount of
Preparation method:
Get the various materials of above-mentioned formula ratio, middle molecular weight sodium chondroitin sulfate and Manganese ascorbate are crossed 80 mesh sieves,, add starch slurry and make soft material, granulate, put 70-80 ℃ of dry back in 12 mesh sieve granulate, promptly with 14 mesh sieves with the appropriate amount of starch mixing.
Embodiment 11
The prescription of ointment:
Mean molecule quantity is 8,000 daltonian low-molecular weight chondroitin sulfate sodium salt 50g
Tristerin 70g
Stearic acid 100g
White vaseline 120g
Liquid Paraffin 100g
Glycerol 120g
Sodium lauryl sulphate 10g
Ethyl hydroxybenzoate 1g
Distilled water 480mL
Preparation method:
With passing through 60 mesh sieves behind the low-molecular weight chondroitin sulfate porphyrize, standby.Get tristerin, stearic acid, white vaseline and liquid Paraffin heat fused are oil phase.In addition glycerol and distilled water are heated to 90 ℃, add sodium lauryl sulphate again and ethyl hydroxybenzoate is dissolved as water.Then water is slowly poured in the oil phase, the limit edged stirs, and until condensation, promptly gets emulsion-type substrate; The low-molecular weight chondroitin sulfate that sieves is added in the above-mentioned substrate, stir promptly.
Embodiment 12
The prescription of gel
Mean molecule quantity is 8,000 daltonian low-molecular weight chondroitin sulfate sodium salt 50g
Carbopol 940 10g
Ethanol 50g
Glycerol 50g
Polysorbate80 20g
Ethyl hydroxybenzoate 1g
Sodium hydroxide 4g
Distilled water adds to 1,000g
Preparation method:
Sodium chondroitin sulfate and carbopol 940, glycerol and polysorbate80 are added the 300mL distilled water mixes, sodium hydroxide is dissolved in adding behind the 100mL distilled water to be gone up liquid and stirs evenly, and ethyl hydroxybenzoate is dissolved in behind the ethanol gradually that adding stirs evenly again, promptly.
Embodiment 13
The prescription of suppository (making 1,000 piece of suppository altogether):
Mean molecule quantity is 8,000 daltonian low-molecular weight chondroitin sulfate sodium salt 300g
S-40 600g
Preparation method:
Get S-40 and in water-bath, melt, the sodium chondroitin sulfate porphyrize, the substrate that adds above-mentioned fusing is ground evenly, and insulation is irritated film promptly.
Embodiment 14
The prescription of membrane (making pelliculae pro cavo oris 4,000 lattice altogether, every lattice sulfur acid chrondroitin 10mg)
Mean molecule quantity 10,000 daltonian chondroitin sulfate zinc salt 40g
Polyvinyl alcohol (PVA17-88) 30g
Sodium carboxymethyl cellulose 15g
Glycerol 25g
Distilled water adds to 1,000g
Preparation method:
With polyvinyl alcohol, sodium carboxymethyl cellulose is used an amount of distilled water immersion, dissolving respectively earlier.Low-molecular weight chondroitin sulfate is dissolved in an amount of distilled water, adds in the film material solution, adding distil water stirs to capacity.Place, treat that bubble eliminates after, film, dry lattice, packing, packing promptly.
Embodiment 15
The prescription of eye drop:
Mean molecule quantity is 8,000 daltonian low-molecular weight chondroitin sulfate sodium 10g
Sodium chloride (osmotic pressure regulator) 9g
Methyl hydroxybenzoate (antibacterial) 0.23g
Propylparaben (antibacterial) 0.11g
Distilled water adds to 1,000mL
Preparation method:
Get methyl hydroxybenzoate, propyl ester, add the dissolved in distilled water that boils, dissolve in chondroitin sulfate and sodium chloride in the time of 60 ℃, filter, adding distil water is to capacity, fill, and 100 ℃, 30 minutes flowing steam sterilizations are promptly.
Embodiment 16
The prescription of aerosol
Mean molecule quantity is 16,000 daltonian low-molecular weight chondroitin sulfate zinc salt 35g
Polyoxyethylene Sorbitan Monooleate 30g
Sorbitan Oleate 35g
Glycerol 250mL
Dodecyl sodium sulfate 20g
F
12 962mL
Distilled water adds to 1,400mL
Preparation method:
Make emulsifying agent with Polyoxyethylene Sorbitan Monooleate, Sorbitan Oleate and dodecyl sodium sulfate, after chondroitin sulfate is soluble in the aqueous phase, be mixed into Emulsion with oil phase, be distributed into 175 bottles, every bottle is pressed into 5,5g F
12Seal and get.
Embodiment 17
The prescription of slow releasing preparation (osmotic pump tablet):
1. label
Mean molecule quantity is 8,000 daltonian sodium chondroitin sulfate 600g
Mannitol (40 order) 285g
Poly(ethylene oxide) (40 orders, molecular weight 5,000,000) 6g
Polyvidone 120g
Ethanol 190mL
Stearic acid (40 order) 12g
2. coating solution
Cellulose acetate (acetyl base value 39.8%) 5g
Cellulose acetate (acetyl base value 32%) 1.5g
Hydroxypropyl cellulose 2.3g
Polyethylene Glycol 3350 0.5g
Dichloromethane 175mL
Methanol 75mL
Preparation method:
1. label preparation: first three kind component in the label prescription is placed blender, mixed 5 minutes; Polyvidone is dissolved in the ethanol, slowly adds in the above-mentioned blending ingredients, stirred 20 minutes, cross 10 mesh sieves and granulate,, behind 10 mesh sieve granulate, add the stearic acid mixing, tabletting in 50 ℃ of dryings 15 hours.
2. coating: use the air suspension technology coating, feed liquor speed 20 ml/min are put coated tablet in following 50 hours of 50 ℃, the condition of relative humidity 50%, in 50 ℃ of drying baker dry 20 hours again.
3. punching: each makes a call to a small delivery aperture at coated tablet upper and lower surface symmetry place, and the aperture is 254 μ m.
Embodiment 18
Passive target and nanoparticle The Application of Technology
Will in/low-molecular-weight chondroitin sulfate makes Polyisobutyl cyanoacrylate nanocapsule (200nm), because its tangible lymph directionality, can improve the antitumous effect of its preparation.
Claims (10)
1, the non-injection-type preparation of molecular weight chondroitin sulfate and/or low-molecular weight chondroitin sulfate and/or both pharmaceutical salts in a kind of containing, it is characterized in that, the molecular weight chondroitin sulfate is that mean molecule quantity is 10 in described, 000-30, chondroitin sulfate in 000 dalton's scope, described low-molecular weight chondroitin sulfate be mean molecule quantity 2,000-10, the chondroitin sulfate in 000 dalton's scope; Also contain pharmaceutically acceptable adjuvant in the described non-injection-type preparation.
2, non-injection-type preparation as claimed in claim 1, it is characterized in that the dosage form of described non-injection-type preparation is to be selected from a kind of in the following dosage forms: tablet, capsule, granule, solution, gel, cream, aerosol, membrane, pill, suppository and eye drop.
3, non-injection-type preparation as claimed in claim 1 is characterized in that, the pharmaceutical salts of described middle molecular weight chondroitin sulfate and/or low-molecular weight chondroitin sulfate is one or more in its sodium salt, potassium salt, calcium salt, zinc salt, iron salt, magnesium salt, the aluminum salt.
4, non-injection-type preparation as claimed in claim 1 is characterized in that, only contains low-molecular weight chondroitin sulfate in the described non-injection-type preparation or only contains middle molecular weight chondroitin sulfate.
5, non-injection-type preparation as claimed in claim 1 is characterized in that, contains low-molecular weight chondroitin sulfate and middle molecular weight chondroitin sulfate in the described non-injection-type preparation simultaneously.
6, non-injection-type preparation as claimed in claim 2 is characterized in that, described non-injection-type preparation is slow releasing preparation, controlled release preparation, targeting delivery formulations, durative action preparation or nano particle preparations.
7, non-injection-type preparation as claimed in claim 1 is characterized in that, described non-injection-type preparation is a compound preparation, and this compound preparation also contains the ancillary drug composition.
8, non-injection-type preparation as claimed in claim 7 is characterized in that, contains pharmaceutical salts, Manganese ascorbate and/or the methylsulfonyl methane of glucosamine in the described non-injection-type preparation.
9, non-injection-type preparation as claimed in claim 8 is characterized in that, the pharmaceutical salts of described glucosamine is its sulfate and/or its hydrochlorate.
10, non-injection-type preparation as claimed in claim 7 is characterized in that, contains collagen, seal oil, Radix Ranunculi Ternati, hyaluronate sodium, vitamin C, vitamin B in the described non-injection-type preparation
12, in the detoxifcation factor, anti-inflammatory factors, the analgesic one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100388210A CN1296052C (en) | 2003-05-07 | 2004-04-30 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031143741A CN1470245A (en) | 2003-05-07 | 2003-05-07 | Low-molecular-weight chondroitin sulfate injecta and its preparation method |
| CN03114374.1 | 2003-05-07 | ||
| CNB2004100388210A CN1296052C (en) | 2003-05-07 | 2004-04-30 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562073A true CN1562073A (en) | 2005-01-12 |
| CN1296052C CN1296052C (en) | 2007-01-24 |
Family
ID=34523610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100388210A Expired - Fee Related CN1296052C (en) | 2003-05-07 | 2004-04-30 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296052C (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293738A (en) * | 2011-08-10 | 2011-12-28 | 济南强生生物科技有限公司 | External preparation for and method treating arthritis |
| CN101653451B (en) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | Health product for keeping joint health and increasing bone density and preparation method thereof |
| CN102600250A (en) * | 2011-01-25 | 2012-07-25 | 中国医学科学院药用植物研究所 | In-situ gel sustained-release preparation of Ranunculus ternatus Thunb., and its preparation method |
| CN102599508A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Preparation for preparing chondroitin glucosamine particles by wet method and preparation method |
| CN104125831A (en) * | 2012-02-29 | 2014-10-29 | 老笃制药株式会社 | Solid composition |
| CN105982912A (en) * | 2015-03-02 | 2016-10-05 | 黄绣川 | Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate |
| CN105193837B (en) * | 2015-09-16 | 2018-08-24 | 浙江康多利药业有限公司 | A kind of creme and preparation method thereof of prevention and treatment joint disease |
| CN108904449A (en) * | 2018-08-20 | 2018-11-30 | 广州云雾雾化应用技术研究院（普通合伙） | A kind of application of mist state chondroitin in the drug for preparing repairing corneal |
| CN109568267A (en) * | 2018-12-28 | 2019-04-05 | 中山市天图精细化工有限公司 | A kind of frost pain-stopping aerosol and preparation method thereof |
| CN109588604A (en) * | 2017-11-13 | 2019-04-09 | 中国水产科学研究院南海水产研究所 | A kind of pinctada fucata glycosaminoglycan effervescent tablet and preparation method thereof |
| CN110548003A (en) * | 2019-10-18 | 2019-12-10 | 吉林大学 | Externally applied chondroitin sulfate nano composition as well as preparation method and application thereof |
| CN111110695A (en) * | 2019-09-30 | 2020-05-08 | 中检科医药科技(北京)集团有限公司 | Use of low molecular weight chondroitin sulfate in preparation of daily chemical products and external preparations |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3405120A (en) * | 1966-01-27 | 1968-10-08 | Green Cross Corp | Low molecular chondroitin sulfate and method for manufacturing the same |
-
2004
- 2004-04-30 CN CNB2004100388210A patent/CN1296052C/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653451B (en) * | 2009-09-04 | 2012-07-18 | 江苏江山制药有限公司 | Health product for keeping joint health and increasing bone density and preparation method thereof |
| CN102600250A (en) * | 2011-01-25 | 2012-07-25 | 中国医学科学院药用植物研究所 | In-situ gel sustained-release preparation of Ranunculus ternatus Thunb., and its preparation method |
| CN102600250B (en) * | 2011-01-25 | 2013-12-18 | 中国医学科学院药用植物研究所 | In-situ gel sustained-release preparation of Ranunculus ternatus Thunb., and its preparation method |
| CN102293738A (en) * | 2011-08-10 | 2011-12-28 | 济南强生生物科技有限公司 | External preparation for and method treating arthritis |
| CN104125831A (en) * | 2012-02-29 | 2014-10-29 | 老笃制药株式会社 | Solid composition |
| CN102599508A (en) * | 2012-03-17 | 2012-07-25 | 江苏艾兰得营养品有限公司 | Preparation for preparing chondroitin glucosamine particles by wet method and preparation method |
| CN105982912A (en) * | 2015-03-02 | 2016-10-05 | 黄绣川 | Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate |
| CN105193837B (en) * | 2015-09-16 | 2018-08-24 | 浙江康多利药业有限公司 | A kind of creme and preparation method thereof of prevention and treatment joint disease |
| CN109588604A (en) * | 2017-11-13 | 2019-04-09 | 中国水产科学研究院南海水产研究所 | A kind of pinctada fucata glycosaminoglycan effervescent tablet and preparation method thereof |
| CN108904449A (en) * | 2018-08-20 | 2018-11-30 | 广州云雾雾化应用技术研究院（普通合伙） | A kind of application of mist state chondroitin in the drug for preparing repairing corneal |
| CN109568267A (en) * | 2018-12-28 | 2019-04-05 | 中山市天图精细化工有限公司 | A kind of frost pain-stopping aerosol and preparation method thereof |
| CN109568267B (en) * | 2018-12-28 | 2021-01-05 | 中山市天图精细化工有限公司 | A kind of frozen analgesic aerosol and preparation method thereof |
| CN111110695A (en) * | 2019-09-30 | 2020-05-08 | 中检科医药科技(北京)集团有限公司 | Use of low molecular weight chondroitin sulfate in preparation of daily chemical products and external preparations |
| CN111110695B (en) * | 2019-09-30 | 2021-06-18 | 中检科医药科技(北京)集团有限公司 | Use of low molecular weight chondroitin sulfate in the preparation of daily chemical products and external preparations |
| CN113456662A (en) * | 2019-09-30 | 2021-10-01 | 中检科医药科技(北京)集团有限公司 | Use of low molecular weight chondroitin sulfate in preparation of daily chemical products and external preparations |
| CN110548003A (en) * | 2019-10-18 | 2019-12-10 | 吉林大学 | Externally applied chondroitin sulfate nano composition as well as preparation method and application thereof |
| CN114028420A (en) * | 2021-12-28 | 2022-02-11 | 杭州拾珍医疗器械有限公司 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1296052C (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1296052C (en) | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate | |
| CN1223341C (en) | Spheroids, methods for their preparation and pharmaceutical compositions | |
| CN1525855A (en) | Oral controlled-release pharmaceutical composition for once-a-day therapy for treating and preventing heart disease and circulatory system diseases | |
| CN1878540A (en) | Taste-masked pharmaceutical compositions containing pH-sensitive polymers | |
| CN1726024A (en) | Preparations comprising fenofibric acid, its physiologically acceptable salts or derivatives | |
| TW200534879A (en) | Coated tablet formulation and method | |
| CN1357328A (en) | Medicine preparation and its production process | |
| CN100340295C (en) | Oral administered compound colloid pectin bismuth preparation and its preparing process | |
| CN1147295C (en) | Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof | |
| CN100335134C (en) | Nimodipine soft capsule and its prepn | |
| CN1543943A (en) | Oral silymarin sustained-release preparation and preparation method thereof | |
| CN1615844A (en) | Development of micro particle silybum marianum preparation | |
| CN1634087A (en) | Compound glucosamine salt sustained-release preparation and its preparation method and application | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1903182A (en) | Miniaturization sarpogrelate hydrochloride oral drug-giving preparation | |
| CN1729998A (en) | Cancer treating | |
| CN1160060C (en) | Compressed composition containing clarified xanthan gum | |
| CN1268327C (en) | Brufen arginine pseudoephedrine hydrochloride compound formulation | |
| CN1611218A (en) | Fixed dose compound preparation of antitubercular drug and its preparing method | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN1634481A (en) | Honeysuckle flower soft capsule and preparation method thereof | |
| CN1660250A (en) | Chinese materia medica preparation for treating dysmenorrhea of women | |
| CN1268060A (en) | Sustained-release oral preparation | |
| CN1209102C (en) | Arginine acetate oral preparation and clinical application thereof | |
| CN1612727A (en) | Stable granulates containing S-adenosylmethionine and process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070124 |